Home  |  Contact

UniProtKB/Swiss-Prot P00966: Variant p.Trp179Arg

Argininosuccinate synthase
Gene: ASS1
Variant information

Variant position:  179
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Tryptophan (W) to Arginine (R) at position 179 (W179R, p.Trp179Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (W) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CTLN1; mild; decreased affinity for aspartate; decreased affinity for citrulline; decreased argininosuccinate synthase activity.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  179
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  412
The length of the canonical sequence.

Location on the sequence:   DLMEYAKQHGIPIPVTPKNP  W SMDENLMHISYEAGILENPK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         DLMEYAKQHGIPIPVTPKNPWSMDENLMHISYEAGILENPK

Mouse                         DLMEYAKQHGIPIPVTPKSPWSMDENLMHISYEAGILENPK

Rat                           DLMEYAKQHGIPIPVTPKSPWSMDENLMHISYEAGILENPK

Bovine                        DLMEYAKQHGIPVPVTPKNPWSMDENLMHISYEAGILENPK

Chicken                       ELMEYAQKHGIPVPVTPKAPWSMDENLMHISYEAGILENPK

Xenopus laevis                DLMEYAKKHNISVPVTPKSPWSMDENLMHISYEGGILENPK

Xenopus tropicalis            DLMEYAKKHNIPVPVTPKDPWSMDENIMHISYEGGILENPK

Zebrafish                     DLMEYAEKHNIPVPVTPKAPWSMDANLMHISYESGILENPK

Drosophila                    DLIAYAQQHGIEVSAKPATPWSTDANILHISYESGILEDPN

Baker's yeast                 DLLDYAAQKGIPVAQTKAKPWSTDENQAHISYEAGILEDPD

Fission yeast                 DLLEYAAAKGIPVTQTTKKPWSMDENIVHCSYEAGILEDPS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 412 Argininosuccinate synthase
Binding site 180 – 180 Citrulline
Binding site 189 – 189 Citrulline
Modified residue 165 – 165 N6-acetyllysine; by CLOCK
Modified residue 176 – 176 N6-acetyllysine; by CLOCK
Modified residue 180 – 180 Phosphoserine
Mutagenesis 165 – 165 K -> QR. Significant loss of acetylation but no decrease in enzyme activity; when associated with Q-176 or R-176.
Mutagenesis 176 – 176 K -> QR. Significant loss of acetylation but no decrease in enzyme activity; when associated with Q-165 or R-165.


Literature citations

Structure of the human argininosuccinate synthetase gene and an improved system for molecular diagnostics in patients with classical and mild citrullinemia.
Haeberle J.; Pauli S.; Linnebank M.; Kleijer W.J.; Bakker H.D.; Wanders R.J.A.; Harms E.; Koch H.G.;
Hum. Genet. 110:327-333(2002)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS CTLN1 LEU-108; ARG-179; VAL-362 AND ARG-390;

Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients.
Gao H.-Z.; Kobayashi K.; Tabata A.; Tsuge H.; Iijima M.; Yasuda T.; Kalkanoglu H.S.; Dursun A.; Tokatli A.; Coskun T.; Trefz F.K.; Skladal D.; Mandel H.; Seidel J.; Kodama S.; Shirane S.; Ichida T.; Makino S.; Yoshino M.; Kang J.-H.; Mizuguchi M.; Barshop B.A.; Fuchinoue S.; Seneca S.; Zeesman S.; Knerr I.; Rodes M.; Wasant P.; Yoshida I.; De Meirleir L.; Abdul-Jalil M.; Begum L.; Horiuchi M.; Katunuma N.; Nakagawa S.; Saheki T.;
Hum. Mutat. 22:24-34(2003)
Cited for: VARIANTS CTLN1 ARG-19; HIS-86; SER-95; SER-96; ASP-117; SER-117; CYS-157; ARG-179; LYS-191; HIS-265; MET-269; CYS-272; LYS-283; TRP-304; GLN-310; SER-324; VAL-362; GLN-363; TRP-363; ILE-389 AND ARG-390;

Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1).
Haeberle J.; Pauli S.; Schmidt E.; Schulze-Eilfing B.; Berning C.; Koch H.G.;
Mol. Genet. Metab. 80:302-306(2003)
Cited for: VARIANTS CTLN1 SER-14; LEU-40; GLN-127; ARG-179; ASP-190; GLU-202; MET-263; MET-269; SER-324; GLY-345 AND VAL-362;

Investigation of citrullinemia type I variants by in vitro expression studies.
Berning C.; Bieger I.; Pauli S.; Vermeulen T.; Vogl T.; Rummel T.; Hoehne W.; Koch H.G.; Rolinski B.; Gempel K.; Haeberle J.;
Hum. Mutat. 29:1222-1227(2008)
Cited for: VARIANTS CTLN1 CYS-265 AND VAL-302; CHARACTERIZATION OF VARIANTS CTLN1 THR-118; ARG-179; VAL-263; CYS-265; VAL-302; SER-324; VAL-362 AND ARG-390; FUNCTION; CATALYTIC ACTIVITY; PATHWAY; BIOPHYSICOCHEMICAL PROPERTIES;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.